Akari Therapeutics PLC ADR AKTX
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
Akari Therapeutics Participates in Virtual Investor “What This Means” Segment Featuring Newly Appointed Chief Business Officer Vatnak Vat-Ho
Akari Therapeutics to Highlight Novel RNA-Splicing ADC Payload Strategy at the 3rd Annual ADC Payload Summit
Akari Therapeutics CEO Highlights Differentiated ADC Payload Strategy and Path Toward Clinical Development in New CEO Corner
Akari Therapeutics Appoints Accomplished Oncology and ADC Deal Executive Vatnak Vat-Ho as Chief Business Officer to Drive Strategic Growth and Partnering
Akari Therapeutics Expands Intellectual Property Portfolio with PCT Filing for ADC Payload Related to RNA Splicing in Cancers
Akari Therapeutics Selected to Showcase Novel PH1 ADC Payload Platform at Leading Global Oncology, ADC and Healthcare Forums
Akari Therapeutics Participates in the Virtual Investor "Why Now" On-Demand Conference
Akari Therapeutics Builds Momentum for AKTX-101 with Compelling Urothelial Cancer Data Supporting Differentiated ADC Strategy
Trading Information
- Previous Close Price
- $7.13
- Day Range
- $7.16–7.65
- 52-Week Range
- $3.02–29.32
- Bid/Ask
- $7.15 / $8.63
- Shares Outstanding
- 2.29M
- Market Cap
- $17.02M
- Volume/Avg
- 22,509 / 64,313
Key Statistics
- Price/Earnings (Normalized)
- 0.45
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Akari Therapeutics PLC is an oncology company developing next-generation antibody-drug conjugates (ADCs) built around novel, proprietary payloads utilizing powerful biology to attack cancer. Its payload, PH1, targets RNA splicing by modulating the spliceosome, a complex machinery in the cell that converts pre-RNA into spliced RNA for translation into vital proteins for cell survival and growth. Its product pipeline is AKTX-101, which targets the Trop2 receptor on cancer cells and, with a proprietary linker, enables it to deliver its novel PH1 payload directly into the tumor with minimal off-target effects. and AKTX-102, an ADC candidate targeting CEACAM5 (Carcinoembryonic Antigen-related Cell Adhesion Molecule-5), a well-validated tumor antigen expressed across multiple solid tumors.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- —
- Total Number of Employees
- 5
- Website
- https://www.akaritx.com
Valuation
Metric | AKTX |
|---|---|
Price/Earnings (Normalized) | 0.45 |
Price/Book Value | 0.70 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
AKTX
Financial Strength
Metric | AKTX |
|---|---|
Quick Ratio | 0.55 |
Current Ratio | 0.60 |
Interest Coverage | −32.32 |
Quick Ratio
AKTX
Profitability
Metric | AKTX |
|---|---|
Return on Assets (Normalized) | −21.69% |
Return on Equity (Normalized) | −42.89% |
Return on Invested Capital (Normalized) | −36.70% |
Return on Assets
AKTX
Biotechnology Industry Comparables
1-Day Chart | Name | Price | Morningstar Rating for Stocks | Capital Allocation | Economic Moat | Market Cap |
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc VRTX | LOCK|wb^zr?? | LOCK|LN^t | $139B | |||
| Moderna Inc MRNA | LOCK|@&^zXH! | LOCK|BN | $101B | |||
| Regeneron Pharmaceuticals Inc REGN | LOCK|r$?&dp^ | LOCK|t@^Jj | $99B | |||
| argenx SE ADR ARGX | LOCK|z!<&R^^ | LOCK|<# | $61B | |||
| BeOne Medicines Ltd ADR ONC | LOCK|mBjVJ%? | LOCK|?bC | $49B | |||
| Royalty Pharma PLC Class A RPRX | LOCK|XlYsB?#y | LOCK|j#KLg | $31B | |||
| Incyte Corp INCY | LOCK|CCjQ!T$ | LOCK|mF | $25B | |||
| BioNTech SE ADR BNTX | LOCK|@KbK^Fn | LOCK|q<y | $22B | |||
| Alnylam Pharmaceuticals Inc ALNY | LOCK|rqtJp# | LOCK|vF?% | $21B | |||
| Jazz Pharmaceuticals PLC JAZZ | LOCK|f!@By%! | LOCK|Kq | $16B |
United States